Skip to main content
TipRanks
Go Ultimate75% OFF

Rigel (RIGL) AI Stock Analysis

1,621 Followers
RIGL

Rigel

(NASDAQ:RIGL)

Select Model
Rating:69Neutral
Price Target:$49.00â–²(10.21% Upside)
Action:downgraded
Date:11/07/26

The score is driven primarily by improved financial performance (profitability, cash generation, and reduced leverage) and strong earnings-call execution/guidance around commercial momentum (notably VEPPANU). This is tempered by weak technicals (bearish trend with negative momentum) and some sustainability questions around unusually high net profitability and rising cost intensity, despite an attractive low P/E valuation.

Positive Factors
Product Sales GrowthRecord product sales and a 17% year-to-date increase show that Rigel’s commercial portfolio is gaining traction across multiple therapies. Continued growth since 2022 supports stronger operating scale, broader patient adoption, and a more durable revenue base.
Negative Factors
Rising Cost IntensityThe sharp increase in R&D, launch, product, commercial, and personnel costs reduced quarterly net income despite revenue growth. Sustained spending may be necessary to build future products, but it creates execution risk if commercial expansion does not convert into lasting operating leverage.

Rigel (RIGL) vs. SPDR S&P 500 ETF (SPY)

-40%-30%-20%-10%0%10%20%30%RIGL+6.67%SPY+15.52%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$837.18M
Dividend Yield
―
Average Volume (3M)
255.43K
Price to Earnings (P/E)
2.6
Beta (1Y)
1.61
Revenue Growth
2.18%
EPS Growth
165.65%
Country
US
Employees
173
Sector
General
Sector Strength
55
Industry
Biotechnology

Rigel Business Overview & Revenue Model

Company Description

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibito...

How the Company Makes Money

Rigel generates revenue primarily from product sales of its marketed therapies and, where applicable, from collaboration- and licensing-related payments. (1) Product revenue: Rigel sells TAVALISSE (fostamatinib) and REZLIDHIA (olutasidenib) in market...

Rigel Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:-2.73%|Next Earnings Date:Mar 09, 2027
Earnings Call SentimentPositive

The call was strongly positive overall. Rigel reported record quarterly product sales, profitability, broad early adoption and favorable access metrics for the VEPPANU launch, continued growth from TAVALISSE and REZLIDHIA, and progress toward R289's next development stages. These positives outweighed the GAVRETO decline, lower net income, increased costs, reduced cash balance and moderation in expected TAVALISSE growth.

Positive Updates

Record Quarterly Product Sales and Continued Growth
Net product sales reached $72.3 million in the third quarter of 2026, the company's highest ever, representing a 13% increase compared with the third quarter of 2025. Year-to-date net product sales were $194.2 million, up 17% from the same period of 2025. Rigel said net product sales have grown at an approximately 35% compound annual growth rate since 2022.

Negative Updates

GAVRETO Sales Declined
GAVRETO generated $9.8 million in third-quarter net product sales, a decrease of 11% compared with the third quarter of 2025.

Company Guidance

For 2026, Rigel updated and narrowed guidance to total revenues in the range of approximately $290 million to $295 million, including approximately $255 million to $260 million in net product sales, excluding VEPPANU, and approximately $35 million in contract revenues, versus previous ranges of $285 million to $295 million, approximately $255 million to $265 million, and previous expectation of approximately $30 million, respectively; the company continues to anticipate reporting positive net income for the full year while funding existing and new clinical development programs and supporting the commercial launch of VEPPANU, plans to complete enrollment and select the recommended Phase 2 dose for R289 by the end of 2026, and is targeting initiating a registration study in 2027.

Rigel Financial Statement Overview

Summary

Financials reflect a strong turnaround with solid profitability and positive operating/free cash flow in 2024–TTM 2026, alongside a significantly de-risked balance sheet and very low current leverage. Constraints are the unusually high net profitability versus revenue in 2025–TTM 2026 (suggesting non-core items may be influencing results) and historical volatility in operating profitability and cash-flow coverage.

Income Statement

78Positive

Balance Sheet

74Positive

Cash Flow

71Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue288.21M294.28M179.28M116.88M120.24M149.24M
Gross Profit258.34M274.66M160.63M109.77M118.49M148.15M
EBITDA83.37M131.56M28.51M-16.98M-53.87M-11.29M
Net Income307.19M367.02M17.48M-25.09M-58.57M-17.91M
Balance Sheet
Total Assets523.88M513.59M163.98M117.22M134.28M167.33M
Cash, Cash Equivalents and Short-Term Investments99.31M154.96M77.32M56.93M58.21M124.97M
Total Debt7.79M53.30M59.97M60.58M41.55M30.57M
Total Liabilities78.77M122.11M160.69M145.87M147.90M136.95M
Stockholders Equity445.11M391.48M3.29M-28.64M-13.62M30.37M
Cash Flow
Free Cash Flow89.93M75.66M31.07M-20.74M-74.21M5.25M
Operating Cash Flow89.92M75.66M31.47M-5.74M-73.76M5.88M
Investing Cash Flow-34.33M-92.36M4.13M-4.30M72.78M-80.04M
Financing Cash Flow-57.48M601.00K-11.64M18.37M6.55M62.67M

Rigel Technical Analysis

Technical Analysis SentimentNegative
Last Price44.46

Price Trends

50DMA47.44Negative
100DMA44.53Negative
200DMA37.59Positive

Market Momentum

MACD-0.98Positive
RSI44.14Neutral
STOCH50.48Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RIGL, the sentiment is Negative. The current price of 44.46 is below the 20-day moving average (MA) of 47.57, below the 50-day MA of 47.44, and above the 200-day MA of 37.59, indicating a neutral trend. The MACD of -0.98 indicates Positive momentum. The RSI at 44.14 is Neutral, neither overbought nor oversold. The STOCH value of 50.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RIGL.

Rigel Risk Analysis

Rigel disclosed 60 risk factors in its most recent earnings report. Rigel reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks
1.We may encounter significant challenges in transitioning development, regulatory, manufacturing and commercialization responsibilities for VEPPANU (vepdegestrant) from Arvinas and Pfizer, and our reliance on third parties for supply, manufacturing and ongoing development activities could adversely affect our ability to successfully launch, commercialize and realize the anticipated benefits of the license agreement.*Q2, 2026
2.The UK's withdrawal from the EU could adversely affect our business.*Q2, 2026
3.The UK's withdrawal from the EU could adversely affect our business.*Q1, 2026

Rigel Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

RIGL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
RIGLRIGL69Neutral$837.18M2.6473.94%―2.18%165.65%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
VSTMVSTM54Neutral$1.03B-4.42-359.49%―649.65%54.01%
RGNXRGNX51Neutral$505.18M-2.38-203.98%―-4.59%8.03%
BCYCBCYC46Neutral$235.88M-1.66-26.02%―194.79%43.93%
LXRXLXRX46Neutral$796.97M-12.32-38.44%―-45.62%21.16%

* General Sector Average

Performance Comparison

-50%0%50%RIGLLXRXVSTMRGNXBCYCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
RIGL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
RIGLRigel Pharmaceuticals44.46-1.76-3.81%
LXRXLexicon Pharmaceuticals1.790.3221.77%
VSTMVerastem Inc8.18-1.09-11.76%
RGNXRegenXBio Inc.7.64-3.61-32.09%
BCYCBicycle Therapeutics3.37-3.10-47.91%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026